糖尿病肾病调脂治疗的临床应用  

Lipidlowering agents in diabetic nephropathy

作　　者：潘瑜[1] 章海涛[1] 

机构地区：[1]南京军区南京总医院肾脏科 国家肾脏疾病临床医学研究中心 全军肾脏病研究所,南京210016

出　　处：《肾脏病与透析肾移植杂志》2015年第2期176-180,共5页Chinese Journal of Nephrology,Dialysis & Transplantation

基　　金：国家科技支撑计划课题(2013BAI09B04)(2015BAI12B05);江苏省临床医学中心项目(BL2012007)

摘　　要：糖尿病肾病(DN)患者心血管事件的风险显著升高,与脂代谢紊乱密切相关。导致脂代谢紊乱的原因复杂多样,长期高血糖诱导血管内皮损伤能进一步增加胆固醇水平、降低高密度胆固醇水平。因此,调脂药物被临床广泛应用于DN的治疗。本文就调脂药物在DN中的临床应用及研究进展做一综述。It is well known that patients with diabetic nephropathy have a high incidence of cardiovascular disease （CVD） .The mechanisms for dyslipidemia in diabetic nephropathy are muhifactorial and complex.Long-term hyperglycemia causes generalized vascular endothelial damage, leading to increased triglyceride levels and decreased high-density lipoprotein cholesterol. The implications of lipid lowering drugs in the treatment of diabetic nephropathy have been considered.The review focuses on the clinical efficacy and safety of lipid lowering drugs in the treatment of diabetic nephropathy.

关 键 词：糖尿病肾病 血脂异常 心血管事件 调脂药物 

分 类 号：R587.2[医药卫生—内分泌]